Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial
Randomised controlled trialHumansWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 70 children with irritable bowel syndrome randomised at three Italian centres (34 treatment, 36 placebo). All completed.
- Dose used in the study
- 200 mg of palmitoylethanolamide with 20 mg of polydatin, three times a day
- Duration
- 12 weeks
- What was measured
- Complete remission, defined as a symptom severity score under 75 points at 12 weeks. Frequency and intensity of abdominal pain.
What the authors reported
Complete remission occurred in 50% of the treatment group versus 22% on placebo (P = 0.015). Days with abdominal pain fell from 2.89 to 1.32 a week in the treatment group and from 2.89 to 2.52 on placebo. No adverse events were recorded.
Limits of this study
The study did not follow children after treatment stopped, so it does not show whether remission lasted. Outcomes were self-reported. The lead author reported that the manufacturer, Epitech, provided the product.
Source
Entry checked against the article page at the publisher (ScienceDirect) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.